Wockhardt Limited · NSE:WOCKPHARMA
Wockhardt — Investor Presentation (June 2026)
36 slides from Wockhardt's investor presentation, Jun 4, 2026
Slide 1: Exchange cover letter - Regulation 30 disclosure
Ref. No.: WOCK/SEC/SE/2026-27/016 4th June, 2026 BSE Limited National Stock Exchange of India Limited Corporate Relations Department Exchange Plaza P J Towers Bandra Kurla Complex Dalal Street Bandra (E) Mumbai - 400 001 Mumbai - 400 051 Scrip Code: 532300 NSE Symbol: WOCKPHARMA Dear Sir/ Madam, Sub
Slide 2: A Global Innovation-Led Healthcare Company
Innovation. Performance. Growth. A Global Innovation-Led Healthcare Company Novel Antibiotics Pharmaceuticals Biotechnology Investor Conference | 04 June 2026 1
Slide 3: Disclaimer
Investor Conference | 04 June 2026 Disclaimer This presentation contains “forward-looking statements” – that is, statements that relate to future, not past events or historical facts. All forward-looking statements are based on judgments derived from the information available to the company at this
Slide 4: Agenda
Investor Conference | 04 June 2026 Agenda Wockhardt’s Strategic Overview and Growth drivers - Dr. Murtaza Khorakiwala (Managing Director) Foray of Zaynich in US - Zahabiya Khorakiwala (Director) Zaynich Strategy in India - Annapurna Das (President- India Business & NCE Emerging Markets) Q&A 3
Slide 5: Agenda
Investor Conference | 04 June 2026 Agenda Wockhardt’s Strategic Overview and Growth drivers - Dr. Murtaza Khorakiwala (Managing Director) Foray of Zaynich in US - Zahabiya Khorakiwala (Director) Zaynich Strategy in India - Annapurna Das (President- India Business & NCE Emerging Markets) Q&A 4
Slide 6: Overview & Business Performance
Investor Conference | 04 June 2026 Overview & Business Performance 5
Slide 7: Global Research-driven multinational
Investor Conference | 04 June 2026 Global Research - driven multinational Novel Antibiotics Biotechnology Pharmaceuticals World-leading discovery engine for Integrated diabetes-biosimilars Branded and specialty first-in-class new chemical entities franchise spanning human insulin pharmaceutical pres
Slide 8: Key Financials
Investor Conference | 04 June 2026 Key Financials INR 3,373 Cr. 51% FY26 Income Y-o-Y EBITDA growth1 INR 630 Cr. 0.10 FY26 EBITDA Net Debt : Equity ratio2 INR 238 Cr. INR 662 Cr. FY26 PBT Cash & Cash Equivalents3 1. FY26 vs FY25 2. As on 31st March 2026, excluding promoter debt 3. As at 31st March 2
Slide 9: Specialty Business growth
Investor Conference | 04 June 2026 Performance 01 Specialty Business growth 23% Contribution to revenues of novel antibiotics & biosimilars Emrok delivered strong growth of ~50%; Market leading anti-MRSA brand 27% Biotech business growth Production scale-up: 2x for Human Insulin & 1.5x for Glargine
Slide 10: Regional Business contribution
Investor Conference | 04 June 2026 Performance 02 Regional Business contribution UK Emerging Markets +13% YoY growth 39% 28% +35% YoY growth Specialty Injectables Strategic business partnership in Brazil, Thailand, Algeria & Malaysia India Ireland 22% 11% +8% YoY growth +16% YoY growth Innovative po
Slide 11: Improved Profitability
Investor Conference | 04 June 2026 Performance 03 Improved Profitability EBITDA (INR Cr.) Profitability Focus +INR 486 Cr. Margin Maximization Focused on high-margin core products to maximise returns 18.6% Margin Supply Chain Optimization 5.4% Margin Streamlined sourcing to build cost resilience 630
Slide 12: Operational Excellence
Investor Conference | 04 June 2026 Performance 04 Operational Excellence Manufacturing Cost Management Corporate-wide Re-structuring Improvements Drove systemic cost reduction Optimized plant capacity Accelerated enterprise-wide through disciplined controls and footprint for transformation initiativ
Slide 13: Key Growth Drivers
Investor Conference | 04 June 2026 Key Growth Drivers 12
Slide 14: Looking Ahead
Investor Conference | 04 June 2026 Looking Ahead Objectives for the next two years — growth acceleration, sustainable operational excellence enabled by AI Novel Antibiotics Pharma Business Launch Zaynich in the US, India, Europe and EM EU growth 03 01 Miqnaf: Extending reach & additional Acc
Slide 15: Biosimilar Diabetes Franchise
Investor Conference | 04 June 2026 Growth 02/04 Biosimilar Diabetes Franchise Manufacturing Focus on Human Insulin Limited competition infrastructure ready & Glargine 6-7 Players Drug substance + Products > US$ 1.5 Billion market size 01 02 03 04 05 06 Integrated end to end Pipeline: Aspart, Deglude
Slide 16: Biosimilars portfolio and end-to-end platform
Investor Conference | 04 June 2026 Growth 02/04 Biosimilars portfolio and end-to-end platform Integrated capabilities from lab to patient — a comprehensive pipeline across Human Insulin and insulin analogs 2 Commercialized products Pipeline Across Human Insulin & Insulin Analogs Recombinant Insulin
Slide 17: Pharma Portfolio
Investor Conference | 04 June 2026 Growth 03/04 Pharma Portfolio India UK Pinewood Diabetes Portfolio: Market 18% covered market share Market leadership- penetration Methadone, Pinamox, Hospital, Pharmacy & Codeine, Flucillin, Cortopin Ortho & Pain: New launches Export segment 7 Filings Regenerative
Slide 18: The Wockhardt Journey
Investor Conference | 04 June 2026 The Wockhardt Journey 2018 — 2023 2023 — 2026 2026 — Future Liquidity Management Profitability Management Scaling Growth Debt restructuring & Exit US Generic Business Zaynich Global Business deleveraging Margin expansion Biotech Acceleration Asset monet
Slide 19: Agenda
Investor Conference | 04 June 2026 Agenda Wockhardt’s Strategic Overview and Growth drivers - Dr. Murtaza Khorakiwala (Managing Director) Foray of Zaynich in US - Zahabiya Khorakiwala (Director) Zaynich Strategy in India - Annapurna Das (President- India Business & NCE Emerging Markets) Q&A 18
Slide 20: Zaynich Approved by US FDA
Investor Conference | 04 June 2026 Zaynich Approved TM by US FDA First Indian discovered drug from lab bench to approval that catapults India in the Global spotlight Indian Origin Best in Class Global Impact discovery 19
Slide 21: ~1.2 Million Gram-negative Hospital Infections in USA
Investor Conference | 04 June 2026 USA: Commercial opportunity ~1.2 Million Gram-negative Hospital Infections in USA 600K 290K 165K Complicated Urinary Tract Complicated Intra Abdominal Other Healthcare Associated Infection Cases Infections Infections 157K 60K Hospital Acquired / Ventilator Blood St
Slide 22: Treatment failures combined with limited alternatives create opportunity for Zaynich
Investor Conference | 04 June 2026 Clinical Development Treatment failures combined with limited alternatives create a meaningful opportunity for ZaynichTM Treatment failure rates for empiric therapy due to carbapenem resistance in high burden settings ~40% for cUTI patients 15-25% Polymicrobial inf
Slide 23: Zaynich tackles pan drug-resistant infections via unique mechanism of action
Investor Conference | 04 June 2026 ZaynichTM tackles pan drug-resistant infections riding on its unique mechanism of action Kills major Targeting multiple Carbapenem resistant penicillin binding Established Safety bacteria that other protein mechanism of Profile drug fails to treat action Safe for p
Slide 24: Zaynich novel antibiotic with strong safety profile
Investor Conference | 04 June 2026 Clinical Development ZaynichTM is a novel antibiotic for Gram-negative infections coupled with a strong safety profile 96.8% 89% >90% 85 Clinical Cure Rate Clinical + Clinical Efficacy in Compassionate use in Global Phase III Microbiological Cure Phase II CRO Study
Slide 25: Leadership on boarded for commercialization of Zaynich
Investor Conference | 04 June 2026 Capabilities Development Leadership on boarded for commercialization of Zaynich Dr. Dennis Deruelle William McNey Chief Medical Officer Chief Commercial Officer Experience: 19+ years Experience: 25+ years Previous Organizations: Vitasora Previous Organizations: IQV
Slide 26: Integrated launch architecture strategy
Investor Conference | 04 June 2026 Launch excellence Strategy to established a “competency & capability heavy, but operationally light” integrated launch architecture Wockhardt USA Leadership team to drive strategy & execution HEOR: showcasing economic benefit of Zaynich Strong market access for wid
Slide 27: Agenda
Investor Conference | 04 June 2026 Agenda Wockhardt’s Strategic Overview and Growth drivers - Dr. Murtaza Khorakiwala (Managing Director) Foray of Zaynich in US - Zahabiya Khorakiwala (Director) Zaynich Strategy in India - Annapurna Das (President- India Business & NCE Emerging Markets) Q&A 26
Slide 28: Zaynich Approved by CDSCO, India
Investor Conference | 04 June 2026 Zaynich Approved ® by CDSCO, India 27
Slide 29: India's Carbapenem Resistance Burden
Investor Conference | 04 June 2026 India: Burden India’s Carbepenem Resistance Burden : Rising CR cases and resistance trends is a reality with improving healthcare access Total Hospitalized CR Rate Organism Trend ~1 Mn + Infections (India) Klebsiella pneumoniae ~52-70% ↑ Rising 600K - Gram negative
Slide 30: Launch Playbook
Investor Conference | 04 June 2026 It takes 2–10 years for innovation to reach Emerging Markets. We want to break the cycle. Challenge the conventional Launch Playbook 29
Slide 31: Zaynich Launch Priorities
Investor Conference | 04 June 2026 India: Launch Plan 1/2 Zaynich Launch Priorities Building Real world evidence (RWE) and driving right usage in right patients is not an option - it is the strategy Drive Accelerated Market Penetration Build Go-To-Market (Share of Voice & Reach) for ≥ 80% patient po
Slide 32: India Patient Access Approach
Investor Conference | 04 June 2026 India: Launch Plan 2/2 India Patient Access Approach CR Burden Led Access for Patient Pool in Private and Public ★ High CR Building experts’ Specialized 360 ° R&D Burden Insights on CR and enabled Scientific Large Tertiary Care co-creating product Knowledge Roll ou
Slide 33: Carbapenem Resistance Burden in Emerging Markets
Investor Conference | 04 June 2026 EM Disease Landscape Carbapenem Resistance Burden in Emerging Markets ~ 1.5 Mn+ CR cases in EM markets · High unmet need for managing CR organism infections • Resistance is rising rapidly across EM markets — outpacing Estimated CR cases per year treatment options ~
Slide 34: India & EM a Multiplier, Not Additive
Investor Conference | 04 June 2026 INDIA & EM a Multiplier , Not Additive Building patient centric Industry-leading business and operating model Market potential : delivering sizeable, Launch : Patient Patient Pool sustainable and profitable Access revenue Millions of patients in Emerging Markets ar
Slide 35: Investor Conference | 04 June 2026
Investor Conference | 04 June 2026 34
Slide 36: Abbreviations
Investor Conference | 04 June 2026 Abbreviations ®: Registered EBITDA : Earnings before interest, PBP: Penicillin-binding proteins taxes, depreciation, and amortization ~: Approximate R&D: Research and Development HABP: Hospital Acquired Bacterial AMR: Anti Microbial Resistance Pneumonia RWE: Real w